Melexis NV (XBRU:MELE) reports robust sales growth and product innovation, but faces profitability pressures due to inflation and limited pricing power.

Despite a 4% sales impact from currency fluctuations, Melexis NV (MLXSF) reports growth in gross results and strengthens its presence in China with new product launches.

Recent share performance and business snapshot Melexis (ENXTBR:MELE) has been under pressure recently, with the share price showing a 0.7% decline over the past day and negative returns over the past month, past 3 months, year to date, and past 3 years. Over the past year, the total return stands at a 1.8% decline, with a 40.8% decline over the past 3 years and a 26.8% decline over the past 5 years, which may influence how existing holders reassess their position. The company reports revenue...

Despite a challenging year, Melexis NV (MLXSF) reports a strong Q4 performance and outlines a promising outlook for 2026.

As European markets experience a steady rise, with the STOXX Europe 600 Index climbing 2.35% and major indices in Germany, Italy, France, and the UK also showing positive momentum, investors are increasingly looking toward dividend stocks as a way to enhance portfolio stability amid subdued inflation levels across the eurozone. In this environment of cautious optimism, selecting dividend stocks with strong fundamentals can provide both income and potential growth opportunities for investors...

As European markets navigate a landscape of mixed monetary policy decisions and economic indicators, the pan-European STOXX Europe 600 Index recently ended slightly lower, reflecting investor caution. In this environment, identifying stocks that may be trading below their estimated value can provide opportunities for investors seeking to capitalize on potential market inefficiencies.

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.